NHJK Holding Corporation Limited

Founded in 2015, New Horizon Health is the pioneer and market leader in China's cancer screening market focusing on early detection of high-incidence cancers. On February 18, 2021, New Horizon Health was successfully listed on the Stock Exchange of Hong Kong under the stock code of 6606.HK, becoming the "First Cancer Screening Stock in China".

New Horizon Health's two colorectal cancer screening products, “Colo Clear” and “Pupu Tube”, as well as aH.pylori screening product “UU Tube”, have been approved by the National Medical Products Administration (NMPA). “Colo Clear” is currently the only cancer screening product approved by the NMPA. UU Tube is currently the only self-conducted aH.pylori screening product for home-use screening test approved in China. In addition, the company has three additional pipeline products for liver, cervical and nasopharyngeal cancer screening. The company holds global rights in all its marketed and pipeline products.